[
  {
    "ts": null,
    "headline": "Argus downgrades Moderna to hold on weak near-term outlook",
    "summary": "Investing.com -- Argus downgraded Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to \"hold\" from \"buy,\" on declining sales of its COVID-19 vaccine and limited near-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=32fd8b1afbaff5bfc3169dd114872ced0d26813610ca59c05ade2e6aabd71a55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734538285,
      "headline": "Argus downgrades Moderna to hold on weak near-term outlook",
      "id": 132046543,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Investing.com -- Argus downgraded Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to \"hold\" from \"buy,\" on declining sales of its COVID-19 vaccine and limited near-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=32fd8b1afbaff5bfc3169dd114872ced0d26813610ca59c05ade2e6aabd71a55"
    }
  },
  {
    "ts": null,
    "headline": "Hedge Funds Think That Moderna, Inc. (MRNA) Will Bounce Back Soon",
    "summary": "We recently compiled a list of the 10 Stocks That Will Bounce Back According To Hedge Funds. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks. With 2024 coming to a close, investors have left several unknown variables behind them. They started out the year […]",
    "url": "https://finnhub.io/api/news?id=cf493b9280a43ee05b49b2c71732ae2030bdef6084e2e712f39e301c034a1360",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734527034,
      "headline": "Hedge Funds Think That Moderna, Inc. (MRNA) Will Bounce Back Soon",
      "id": 132046544,
      "image": "https://s.yimg.com/ny/api/res/1.2/ss7LBw0NkRteO60GW_xAKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3355ab936103e2e5a7e230b963727612",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Stocks That Will Bounce Back According To Hedge Funds. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks. With 2024 coming to a close, investors have left several unknown variables behind them. They started out the year […]",
      "url": "https://finnhub.io/api/news?id=cf493b9280a43ee05b49b2c71732ae2030bdef6084e2e712f39e301c034a1360"
    }
  },
  {
    "ts": null,
    "headline": "3 No-Brainer Biotech Stocks to Buy With $200 Right Now",
    "summary": "Here are three no-brainer biotech stocks to buy with $200 right now.  Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere.  You can scoop up a share of BioNTech for less than $120 at the time of this writing.",
    "url": "https://finnhub.io/api/news?id=0d0f77c2d25b1803db99dfa7b022066089ab4755a7df84ac8c50a457d626ad23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734518640,
      "headline": "3 No-Brainer Biotech Stocks to Buy With $200 Right Now",
      "id": 132041210,
      "image": "https://g.foolcdn.com/editorial/images/801302/scientist-in-lab-young-african-american-female.jpg",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Here are three no-brainer biotech stocks to buy with $200 right now.  Biotech stocks usually appeal more to aggressive growth investors, while value investors typically prefer to look elsewhere.  You can scoop up a share of BioNTech for less than $120 at the time of this writing.",
      "url": "https://finnhub.io/api/news?id=0d0f77c2d25b1803db99dfa7b022066089ab4755a7df84ac8c50a457d626ad23"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: Cutting Costs Might Not Be Enough",
    "summary": "Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is a Sell.",
    "url": "https://finnhub.io/api/news?id=cf649bc911d6c359a313e27f9b82f9f0a66b805e13da15f4127f2c803a19ee66",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734484053,
      "headline": "Moderna: Cutting Costs Might Not Be Enough",
      "id": 132035924,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303457428/image_1303457428.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is a Sell.",
      "url": "https://finnhub.io/api/news?id=cf649bc911d6c359a313e27f9b82f9f0a66b805e13da15f4127f2c803a19ee66"
    }
  }
]